19. The isolated monoclonal antibody of claim 3, wherein the isolated monoclonal antibody binds to at least two of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3.

20. The isolated monoclonal antibody of claim 3, wherein the isolated monoclonal antibody binds to at least four of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3.

21. The isolated monoclonal antibody of claim 3, wherein the monoclonal antibody blocks binding of PCSK9 to LDLR by at least 80%.

22. The isolated monoclonal antibody of claim 19, wherein the monoclonal antibody blocks binding of PCSK9 to LDLR by at least 80%.

23. The isolated monoclonal antibody of claim 20, wherein the monoclonal antibody blocks binding of PCSK9 to LDLR by at least 80%.

24. A monoclonal antibody or fragment thereof that specifically binds to human PCSK9 and is neutralizing in that an excess of said monoclonal antibody or fragment thereof is capable of reducing the quantity of human PCSK9 bound to LDLR in an *in vitro* competitive binding assay, said monoclonal antibody or fragment thereof comprising a combination of a light chain variable domain and a heavy chain variable domain selected from the group of combinations consisting of:

a light chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 9 and a heavy chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 71;

a light chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 10 and a heavy chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 72;

a light chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 12 and a heavy chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 67;

53. A monoclonal antibody or fragment thereof of any one of claims 1-47 produced by the expression of recombinant DNA in the host cell of claim 50 or the hybridoma of claim 51.

54. The method of claim 52 or the monoclonal antibody or fragment thereof, wherein the host cell is selected from the group consisting of Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells, and human epithelial kidney 293 cells.

55. A pharmaceutical composition comprising at least one monoclonal antibody or fragment thereof according to any one of claims 1 to 47, or 53 and a pharmaceutically acceptable excipient.

56. The pharmaceutical composition of claim 55, wherein the pharmaceutical composition is to be administered prior to, concurrent with, or subsequent to, the administration of at least one other therapeutic agent, wherein optionally the other therapeutic agent is a statin.

57. A kit for the treatment of cholesterol related disorders comprising the composition of claims 55 or 56.

58. Use of the monoclonal antibody or fragment thereof of any one of claims 1 to 47 or 53 in the manufacture of a medicament for treating or preventing a condition selected from hypercholesterolemia, cardiovascular disease, metabolic syndrome, diabetes, stroke, and dyslipidemia.

59. The monoclonal antibody or fragment thereof of any one of claims 27 to 29, wherein each CDR is defined in accordance with the Kabat definition, the Chothia definition, the combination of the Kabat definition and the Chothia definition, the AbM definition, or the contact definition of CDR.

60. The monoclonal antibody or fragment thereof of Claim 59, wherein each CDR is defined in accordance with the CDR definition of Kabat.